Request Trial
official_portrait_of_michelle_donelan_mp
(Photo source UK Parliament website. Used under Creative Commons).
7 September 2023FeaturesPharmaSarah Speight
|

‘One of the most positive announcements since Brexit’: UK lawyers react to new Horizon funding deal

Today, the British scientific community woke to the news that the UK has finally rejoined Horizon Europe, the European Union’s €95.5 billion ($102 billion) research funding programme.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Pharma
Novartis pursues Apotex over copies of $2bn skin cancer drug franchise
8 October 2026   Following ANDA litigation over Tafinlar earlier this year, the Swiss multinational has sued the generics maker over its proposed version of Mekinist, asserting patents that cover both the composition and treatment regimen.
Pharma
MSD’s Keytruda hit by eight-country ban across Europe
8 October 2026   Rival Halozyme secures a major patent victory against the pharma giant, blocking the subcutaneous version of its blockbuster cancer drug Keytruda across eight countries as MSD faces mounting pressure ahead of key patent expirations.
Pharma
Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom
6 October 2026   Day one of the UK patent trial over blockbuster drug Jardiance put a lack of biological data, disputed evidence of testing and the limits of scientific prediction under the spotlight.


Editor's picks

Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom
Pharma
Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom
6 October 2026

Editor's picks

Pharma
Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom
6 October 2026
Pharma
Lilly loses Fed Circ rehearing bid, sparking enablement questions
1 October 2026
Pharma
Takeda sees off UK challenge to Elvanse SPC
28 September 2026
Pharma
Behind the case: How Novartis defended its blockbuster Entresto in the UK
22 September 2026
Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026
Regulation & Industry
Perfect Pitch: Inside the scheme that gets junior lawyers selling to clients
14 September 2026

More features

Novartis pursues Apotex over copies of $2bn skin cancer drug franchise
MSD’s Keytruda hit by eight-country ban across Europe
WATCH: LEO Pharma head of IP rights on doing more with less
Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom
Latham adds ‘exceptional’ ITC expert and 5th trial lawyer in a year
Fish & Richardson nets patent litigator to grow European practice
Lilly loses Fed Circ rehearing bid, sparking enablement questions
Takeda sees off UK challenge to Elvanse SPC